StockData
Veracyte, Inc. logo

Veracyte, Inc. (VCYT) stock

VCYTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/3034% below fair value
$24.23+0.22 (+0.92%)

Close on Nov 17, 2026Market cap $1.95BP/E 17.3Yield –

Veracyte enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Veracyte's enterprise value was $1.72B on Nov 11, 2026, against $3.42B a year earlier. Over the last 5 years it ranged from $1.03B to $4.42B, with a median of $1.81B.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$1.72B-42.9%
2025Dec 31, 2025$3.01B+7.8%
2024Dec 31, 2024$2.79B+54.8%
2023Dec 29, 2023$1.80B+17.7%
2022Dec 30, 2022$1.53B-44.5%
2021Dec 31, 2021$2.76B+11.2%
2020Dec 31, 2020$2.48B+112.8%
2019Dec 31, 2019$1.17B+155.6%
2018Dec 31, 2018$456.68M+122.7%
2017Dec 29, 2017$205.07M-2.1%
2016Dec 30, 2016$209.45M+32.5%
2015Dec 31, 2015$158.02M-11.4%
2014Dec 31, 2014$178.26M+4555.1%
2013Dec 31, 2013$3.83M–

More Veracyte figures

See a number that looks wrong?